Yun Soo Park1, Seok Mo Lee1, Ji Sun Park1, Sang Kyun Bae2, Hye-Kyung Shim2, Won-Sik Lee3, Sang-Min Lee3. 1. 1Department of Nuclear Medicine, Busan Paik Hospital, University of Inje College of Medicine, 75 Bokji-ro, Busanjin-gu, Busan, 47392 Republic of Korea. 2. 2Department of Nuclear Medicine, Haundae Paik Hospital, University of Inje College of Medicine, 875 Haeun-daero, Haeundae-gu, Busan, 48108 Republic of Korea. 3. 3Department of Internal Medicine, Busan Paik Hospital, University of Inje College of Medicine, 75 Bokji-ro, Busanjin-gu, Busan, 47392 Republic of Korea.
Abstract
OBJECTIVES: This study aimed to determine the value of clinical prognostic factors and semiquantitative metabolic parameters from initial staging fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography (F-18 FDG PET/CT) in non-Hodgkin lymphoma (NHL) patients treated with stem cell transplantation (SCT). METHODS: A total of 39 malignant lymphoma patients who underwent initial staging F-18 FDG PET/CT were enrolled in this study. SUVmax, MTV_wb, and TLG_wb were measured during the initial staging PET/CT. Receiver operating characteristic curve (ROC) analysis was adopted to dichotomize continuous variables. Log-rank test and Cox proportional hazard regression analysis were used to evaluate disease-free survival (DFS) rate. RESULTS: Among the 39 patients with malignant lymphoma, 17 (43.6%) had a relapse. For several clinical factors such as age, ECOG performance score, AMC/ALC score, stages, and revised International Prognostic Index score, differences between the two dichotomized groups were statistically insignificant. In univariate analysis, DFS estimates were 71.0 ± 7.8 months and 18.0 ± 5.9 months in high-SUVmax and low-SUVmax group, respectively (P < 0.01). For MTV_wb, DFS estimates were 46.6 ± 12.4 months and 69.1 ± 8.5 months in high-MTV_wb and low-MTV_wb group, respectively (P = 0.12). For TLG_wb, DFS estimates were 65.3 ± 7.5 months and 13.7 ± 8.6 months in high-TLG_wb and low-TLG_wb group, respectively (P = 0.02). In Cox proportional hazard regression analysis, only MTV_wb showed statistical significance (HR 3.01, 95% CI 1.04-8.74, P = 0.04). CONCLUSION: In NHL patients treated with SCT, the MTV_wb of initial staging F-18 FDG PET/CT was an independent prognostic factor.
OBJECTIVES: This study aimed to determine the value of clinical prognostic factors and semiquantitative metabolic parameters from initial staging fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography (F-18 FDG PET/CT) in non-Hodgkin lymphoma (NHL) patients treated with stem cell transplantation (SCT). METHODS: A total of 39 malignant lymphoma patients who underwent initial staging F-18 FDG PET/CT were enrolled in this study. SUVmax, MTV_wb, and TLG_wb were measured during the initial staging PET/CT. Receiver operating characteristic curve (ROC) analysis was adopted to dichotomize continuous variables. Log-rank test and Cox proportional hazard regression analysis were used to evaluate disease-free survival (DFS) rate. RESULTS: Among the 39 patients with malignant lymphoma, 17 (43.6%) had a relapse. For several clinical factors such as age, ECOG performance score, AMC/ALC score, stages, and revised International Prognostic Index score, differences between the two dichotomized groups were statistically insignificant. In univariate analysis, DFS estimates were 71.0 ± 7.8 months and 18.0 ± 5.9 months in high-SUVmax and low-SUVmax group, respectively (P < 0.01). For MTV_wb, DFS estimates were 46.6 ± 12.4 months and 69.1 ± 8.5 months in high-MTV_wb and low-MTV_wb group, respectively (P = 0.12). For TLG_wb, DFS estimates were 65.3 ± 7.5 months and 13.7 ± 8.6 months in high-TLG_wb and low-TLG_wb group, respectively (P = 0.02). In Cox proportional hazard regression analysis, only MTV_wb showed statistical significance (HR 3.01, 95% CI 1.04-8.74, P = 0.04). CONCLUSION: In NHL patients treated with SCT, the MTV_wb of initial staging F-18 FDG PET/CT was an independent prognostic factor.
Authors: S H Lim; S H Hyun; H S Kim; J Y Lee; K H Yoo; K S Jung; H-N Song; J Cho; S Park; Y H Ko; S J Kim; J Y Choi; W S Kim Journal: Bone Marrow Transplant Date: 2016-02-08 Impact factor: 5.483
Authors: Craig S Sauter; Matthew J Matasar; Jessica Meikle; Heiko Schoder; Gary A Ulaner; Jocelyn C Migliacci; Patrick Hilden; Sean M Devlin; Andrew D Zelenetz; Craig H Moskowitz Journal: Blood Date: 2015-03-10 Impact factor: 22.113
Authors: D C Linch; D Winfield; A H Goldstone; D Moir; B Hancock; A McMillan; R Chopra; D Milligan; G V Hudson Journal: Lancet Date: 1993-04-24 Impact factor: 79.321
Authors: Alexander Greb; Julia Bohlius; Sven Trelle; Daniel Schiefer; Carmino A De Souza; Christian Gisselbrecht; Tanin Intragumtornchai; Ulrich Kaiser; Hanneke C Kluin-Nelemans; Maurizio Martelli; Noel Jean Milpied; Gino Santini; Leo F Verdonck; Umberto Vitolo; Guido Schwarzer; Andreas Engert Journal: Cancer Treat Rev Date: 2007-04-02 Impact factor: 12.111
Authors: Byung Hyun Byun; Im Il Na; Gi Jeong Cheon; Hye Jin Kang; Kyeong Min Kim; Seung-Sook Lee; Baek-Yeol Ryoo; Chang Woon Choi; Sang Moo Lim; Sung Hyun Yang Journal: Ann Nucl Med Date: 2008-11-04 Impact factor: 2.668
Authors: J Blay; F Gomez; C Sebban; T Bachelot; P Biron; C Guglielmi; A Hagenbeek; R Somers; F Chauvin; T Philip Journal: Blood Date: 1998-11-15 Impact factor: 22.113
Authors: Maroun Karam; Ashar Ata; Kevin Irish; Paul J Feustel; Felix M Mottaghy; Sigrid G Stroobants; Gregor E Verhoef; Surya Chundru; Vonda Douglas-Nikitin; Ching-yee Oliver Wong; Lieselot M Brepoels Journal: Nucl Med Commun Date: 2009-10 Impact factor: 1.690
Authors: Ryan D Gentzler; Andrew M Evens; Alfred W Rademaker; Bing B Weitner; Bharat B Mittal; Gary L Dillehay; Adam M Petrich; Jessica K Altman; Olga Frankfurt; Daina Variakojis; Seema Singhal; Jayesh Mehta; Stephanie Williams; Lynne Kaminer; Leo I Gordon; Jane N Winter Journal: Br J Haematol Date: 2014-03-15 Impact factor: 6.998